BIO-TECHNE Corp(TECH)Stock Analysis

TECH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BIO-TECHNE Corp (TECH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TECH at 59.6/100 on a 32-signal composite quality model, placing it at rank #911 of 2,879 stocks — the top half of the AI-ranked universe. TECH scores in the top quartile across free cash flow (75.3). Areas of concern include earnings quality (32.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 31.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), BIO-TECHNE Corp reports quarterly revenue of $311.4M, net income of $51.0M, free cash flow of $77.6M. Top institutional holders of TECH by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, MORGAN STANLEY, based on the most recent SEC filings. TECH trades on the Nasdaq exchange and files with the SEC under CIK 842023. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TECH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIO-TECHNE Corp directly from SEC EDGAR. BIO-TECHNE Corp's 13F Pro composite quality score has ranged between 8 and 74 since 2021, currently 59.6 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.